La restricción a la comercialización de genéricos de la India por parte de las empresas farmacéuticas, a través de las leyes de patentes de la Unión Europea y sus efectos en el desarrollo humano de los países en vía de desarrollo : 2005-201

Abstract

In the last 10 years, the multinational pharmaceutical companies have found in the patent laws of developed countries of the European Union, a mean to restrict the marketing of generic medicines produced by emerging countries like India. The latter, thanks to compulsory licenses allowed by TRIPS have offered an alternative access to medicines to those developing States whose manufacturing capacities are insufficient or nonexistent. This article focuses on the collision between international law and domestic law that has produced such restriction and analyzes how this situation has undermined the capacity of developing States to guarantee their population’s right to health as a core element of human development. The categories used are the right to health and human development, in opposition to medicine patent laws of the European Union and the interests of multinational pharmaceutical companies.